A drug-releasing polymer composition is disclosed. It may include a major component, which may be ethylene vinyl acetate, and may further include at least one or two release-modifying materials, and may further include at least one or two drugs. The release-modifying materials may be polyethylene glycol and polycaprolactone. The drugs may be minocycline and rifampin. There may be an interaction such that in the presence of two different release-modifying materials, drug release may be greater than with either release-modifying material alone. There may be an interaction such that in the presence of two drugs, drug release may be greater than with either drug alone, and antibacterial performance may be enhanced. Release durations as long as two months are possible. In addition, the composition can be provided on a medical device that is configured for implanting in body tissue for an extended time period.

Methods and devices for the repair of articular tissue using collagen material are provided. Compositions of collagen material and related kits are also provided.

A medical implant system is described for inhibiting infection associated with a joint prosthesis implant. An inventive system includes an implant body made of a biocompatible material which has a metal component disposed on an external surface of the implant body. A current is allowed to flow to the metal component, stimulating release of metal ions toxic to microbes, such as bacteria, protozoa, fungi, and viruses. One detailed system is completely surgically implantable in the patient such that no part of the system is external to the patient while the system is in use. In addition, externally controlled devices are provided which allow for modulation of implanted components.

Provided herein is a drug delivery device and composition, such as a particle, comprising conditioned medium. Also provided herein is a method of preparing polymeric particles for release of conditioned medium. Further, a tissue growth scaffold comprising particles for release of conditioned medium is provided.

The invention concerns a method for coating a vascular endoprosthesis, wherein the vascular endoprosthesis is at least partially wetted with a first solution of an active ingredient and the areas of the vascular endoprosthesis at least partially wetted with the first solution of the active ingredient are at least partially wetted with a liquid containing water and/or at least an alcohol. The additional wetting with a liquid containing water/alcohol imparts a different consistency to the active ingredient layer, specifically making it is less transparent and lacquer-like and more chalklike and opaque. It has been found that such an active ingredient layer provides better transfer of the active ingredient to the blood vessels in which the vascular endoprosthesis is implanted.

Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.

Described herein are methods that result in less cell death resulting from myocardial infarction than would otherwise occur in an individual who has suffered myocardial infarction. Also described are compositions useful in reducing cell death post myocardial infarction.

The disclosure concerns various devices implemented to provide a therapeutic gas rich environment to promote healing, reduce fibrosis and scar formations while maintaining anti-inflammatory, anti-thrombotic, antimicrobial, and vasodilating properties. The device generally includes a gas-donor composition that is embedded within a fibrous holding layer. Coupled to one side of the fibrous holding layer is a water-permeable layer and coupled to an opposite side of the fibrous holding layer is a gas-permeable layer. The water-permeable layer is configured to receive and communicate water to the gas-donor composition, wherein upon contact with the water, the gas-donor composition is configured to deliver a therapeutic gas through the gas-permeable layer to a treatment site of a subject.

Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

A photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient is disclosed herein. In one embodiment, a treatment laser is applied to a body portion of a patient using a painting technique, the treatment laser being configured to provide paint brush-type photodynamic therapy (PPDT) using the painting technique to the body portion of the patient by emitting light of a predetermined wavelength that is absorbed by tissue of the body portion of the patient to which a photosensitizer has been applied, the body portion of the patient being afflicted by a medical condition. The application of the treatment laser to the body portion of a patient using the painting technique treats the medical condition, reduces the symptoms associated with the medical condition, and/or alleviates the medical condition.